Karel J. van Erpecum

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Frederik Nevens, Pietro Andreoné, G. Mazzella et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Raffaella Maria Gadaleta, Karel J. van Erpecum, Bas Oldenburg et al. · Gut · 2011 · 851 citations

Life Sciences, Immunology, Pharmacology +17

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

Kirsten Boonstra, Rinse K. Weersma, Karel J. van Erpecum et al. · Hepatology · 2013 · 720 citations · Full text

Medicine, Internal Medicine, Oncology +12

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

Edith M.M. Kuiper, Bettina E. Hansen, Richard A. de Vries et al. · Gastroenterology · 2009 · 460 citations

Medicine, Pathology, Drug Metabolism +13

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

Andreas E. Kremer, Job J.W.W. Martens, Wim Kulik et al. · Gastroenterology · 2010 · 406 citations

Life Sciences, Biochemistry, Physiology +9